Insider Trading April 15, 2026 04:36 PM

Verisign Executive Sells $134,489 in Stock; Shares Remain Above Insider's Sale Price

General Counsel Thomas Indelicarto disposes of 498 shares amid company profitability and mixed quarter results

By Avery Klein VRSN
Verisign Executive Sells $134,489 in Stock; Shares Remain Above Insider's Sale Price
VRSN

Thomas C. Indelicarto, Verisign's Executive Vice President, General Counsel & Secretary, disclosed the sale of 498 shares on April 14, 2026, for $270.06 each, totaling $134,489. The company reported Q4 2025 revenue that topped forecasts but an EPS miss; shares trade above the sale price while third-party analysis flags the stock as overvalued relative to its Fair Value estimate.

Key Points

  • Indelicarto sold 498 Verisign shares on April 14, 2026, for $270.06 each, totaling $134,489; he retains 38,202.258 shares.
  • Verisign reported Q4 2025 revenue of $425.3 million, slightly above forecasts, but EPS of $2.23 missed expectations of $2.35, a 5.11% negative surprise.
  • Shares trade at $275.30, up nearly 11% year-to-date, while InvestingPro analysis categorizes VRSN as overvalued and places it on its Most Overvalued list. Sectors impacted include internet services/domain registry and the broader technology equity market.

Thomas C. Indelicarto, who serves as Executive Vice President, General Counsel & Secretary at Verisign Inc (NASDAQ:VRSN), reported a personal stock sale in a Form 4 filing with the Securities and Exchange Commission. According to that filing, Indelicarto sold 498 shares of common stock on April 14, 2026.

The transaction was executed at a per-share price of $270.06, producing total proceeds of $134,489. After completing the sale, the filing indicates Indelicarto directly holds 38,202.258 shares of Verisign common stock.

Verisign's share price was quoted at $275.30 at the time of the report, representing a near 11% gain year-to-date. However, third-party InvestingPro analysis cited in related materials places the shares above its Fair Value estimate and lists the company among InvestingPro's Most Overvalued names.

Despite the insider disposition, Verisign continues to report notably high profitability on product sales and services. The company posts gross profit margins of 88%, a metric highlighted as indicative of its leading role in domain registry services.

For investors seeking additional data, a Pro Research Report is available for VRSN and more than 1,400 other U.S. equities, according to the referenced materials.


Operational and earnings details for the company include its fourth-quarter 2025 results. Verisign recorded revenue of $425.3 million for that quarter, a figure described as slightly above analysts' forecasts. Earnings per share, however, were reported at $2.23, below the expected $2.35, constituting a negative surprise of 5.11% relative to consensus estimates.

The juxtaposition of a modest revenue beat with an EPS shortfall is noted as a mixed outcome in the reported results. No recent analyst upgrades or downgrades were disclosed in the materials, leaving market participants to weigh the reported revenue strength against the earnings miss.

This report confines itself to the details disclosed in regulatory filings and company reports referenced above.

Risks

  • Insider sale may be interpreted negatively by some equity investors, potentially influencing short-term market sentiment for Verisign shares - impacts the technology and equities sectors.
  • An EPS shortfall versus expectations introduces uncertainty about near-term earnings momentum despite a revenue beat, affecting investor assessment of company profitability - impacts financial markets and equity analysts' coverage.
  • Third-party valuation assessments that flag the stock as overvalued relative to Fair Value could dampen investor appetite or trigger re-evaluation by value-focused funds - impacts investment strategies and institutional flows.

More from Insider Trading

OrbiMed Expands Stake in Traws Pharma via Strategic Private Placement Apr 28, 2026 Rexford Industrial Realty General Counsel Completes $1.18 Million Stock Sale Apr 28, 2026 Bicara Therapeutics CMO Executes Rule 10b5-1 Trading Plan Involving Share Sales and Option Exercises Apr 28, 2026 Abbott Laboratories Director Daniel Starks Executes Substantial Open Market Share Purchase Apr 28, 2026 BlackRock President Robert Kapito Executes $9.2 Million Share Sale Apr 28, 2026